Inventor · disambiguated record
Agnes Eva Hamburger
Also filed as: HAMBURGER AGNES · HAMBURGER AGNES E · HAMBURGER AGNES EVA
35 granted patents·18 pending applications·602 citations·filing 2009–2024
98Inventor score
Top patents by PatentIndex Score
53 records- 0198US8642546B2FGF21 mutant fusion polypeptides and uses thereofBELOUSKI EDWARD JOHN·Filed 2011·Granted Feb 4, 2014·64 cites·11 claims
- 0298US8410051B2FGF21 mutants and uses thereofBELOUSKI EDWARD JOHN·Filed 2011·Granted Apr 2, 2013·63 cites·21 claims
- 0398US8361963B2Uses of FGF21 polypeptides comprising two or more mutationsAMGEN INC·Filed 2011·Granted Jan 29, 2013·64 cites·4 claims
- 0498US8034770B2FGF21 polypeptides comprising two or more mutationsAMGEN INC·Filed 2009·Granted Oct 11, 2011·63 cites·15 claims
- 0597US8835385B2FGF21 polypeptides comprising two or more mutations and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Sep 16, 2014·48 cites·26 claims
- 0697US8795985B2FGF 21 polypeptides comprising two or more mutations and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Aug 5, 2014·48 cites·18 claims
- 0797US8618053B2FGF21 mutants multimers and uses thereofBELOUSKI EDWARD JOHN·Filed 2012·Granted Dec 31, 2013·45 cites·18 claims
- 0897US8188040B2FGF21 mutants and uses thereofBELOUSKI EDWARD JOHN·Filed 2010·Granted May 29, 2012·59 cites·21 claims
- 0996US11254726B2LILRB1-based chimeric antigen receptorA2 BIOTHERAPEUTICS INC·Filed 2021·Granted Feb 22, 2022·16 cites·16 claims
- 1095US9365653B2Human PAC1 antibodiesAMGEN INC·Filed 2014·Granted Jun 14, 2016·24 cites·27 claims
- 1194US10053507B2Human PAC1 antibodiesAMGEN INC·Filed 2017·Granted Aug 21, 2018·6 cites·19 claims
- 1294US9822178B2Human PAC1 antibodiesAMGEN INC·Filed 2016·Granted Nov 21, 2017·6 cites·29 claims
- 1394US9273106B2FGF mutants with reduced proteolysis and aggregationAMGEN INC·Filed 2013·Granted Mar 1, 2016·9 cites·21 claims
- 1493US11072640B2Methods of treating non-alcoholic steatohepatitis using FGF21 mutantsAMGEN INC·Filed 2018·Granted Jul 27, 2021·3 cites·12 claims
- 1593US10011642B2Methods of treating of diabetes and obesity using FGF21 mutantsAMGEN INC·Filed 2016·Granted Jul 3, 2018·4 cites·28 claims
- 1692US9862752B2Growth differentiation factor 15 (GDF-15) constructsAMGEN INC·Filed 2014·Granted Jan 9, 2018·16 cites·27 claims
- 1792US9714276B2Growth differentiation factor 15 (GDF-15) polypeptidesAMGEN INC·Filed 2013·Granted Jul 25, 2017·17 cites·18 claims
- 1891US11891435B2Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereofAMGEN INC·Filed 2021·Granted Feb 6, 2024·1 cites·24 claims
- 1991US10822408B2PACAP antibodies and uses thereofAMGEN INC·Filed 2016·Granted Nov 3, 2020·10 cites·23 claims
- 2091US10738110B2PAC1 antibodies and uses thereofAMGEN INC·Filed 2019·Granted Aug 11, 2020·3 cites·17 claims
- 2191US10336798B2Growth differentiation factor 15 (GDF-15) polypeptidesAMGEN INC·Filed 2017·Granted Jul 2, 2019·9 cites·21 claims
- 2291US9676851B2Human PAC1 antibodiesAMGEN INC·Filed 2014·Granted Jun 13, 2017·6 cites·20 claims
- 2391US2025136653A1FGF21 Mutants and Uses ThereofAMGEN INC·Filed 2024·Application pending·0 cites
- 2490US12195513B2LILRB1-based chimeric antigen receptorA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Jan 14, 2025·1 cites·18 claims
- 2590US12187775B2LILRB1-based chimeric antigen receptorA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Jan 7, 2025·1 cites·38 claims
- 2690US10894814B2Growth differentiation factor 15 (GDF-15) constructsAMGEN INC·Filed 2017·Granted Jan 19, 2021·4 cites·25 claims
- 2790US2024076333A1FGF21 Mutants and Uses ThereofAMGEN INC·Filed 2023·Application pending·0 cites
- 2888US9493530B2FGF21 mutants comprising a mutation at position 98, 171 and/or 180AMGEN INC·Filed 2014·Granted Nov 15, 2016·10 cites·25 claims
- 2985US11248043B2Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereofAMGEN INC·Filed 2020·Granted Feb 15, 2022·1 cites·33 claims
- 3084US11739131B2Growth differentiation factor 15 (GDF-15) polypeptidesAMGEN INC·Filed 2019·Granted Aug 29, 2023·1 cites·6 claims
- 3184US2024368236A1Growth differentiation factor 15 (gdf-15) constructsAMGEN INC·Filed 2024·Application pending·0 cites
- 3281US2024150448A1Pac1 antibodies and uses thereofAMGEN INC·Filed 2023·Application pending·0 cites
- 3380US11840558B2Methods of treating non-alcoholic steatohepatitis using FGF21 mutantsAMGEN INC·Filed 2021·Granted Dec 12, 2023·0 cites·23 claims
- 3479US12037377B2LILRB1-based chimeric antigen receptorA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Jul 16, 2024·0 cites·24 claims
- 3575US10793631B2Human PAC1 antibodiesAMGEN INC·Filed 2019·Granted Oct 6, 2020·0 cites·20 claims
- 3671US2023029341A1Nucleic acid encoding lilrb1-based chimeric antigen receptorA2 BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 3770US11602543B2Compositions and methods for treating mesothelin positive cancersA2 BIOTHERAPEUTICS INC·Filed 2022·Granted Mar 14, 2023·0 cites·27 claims
- 3870US2021079051A1Growth differentiation factor 15 (gdf-15) constructsAMGEN INC·Filed 2020·Application pending·0 cites
- 3969US10472417B2Human PAC1 antibodiesAMGEN INC·Filed 2018·Granted Nov 12, 2019·0 cites·15 claims
- 4068US10294298B2Human PAC1 antibodiesAMGEN INC·Filed 2017·Granted May 21, 2019·0 cites·19 claims
- 4168US2023277590A1Compositions and methods for treating mesothelin positive cancersA2 BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4263US11780914B2PACAP antibodies and uses thereofAMGEN INC·Filed 2020·Granted Oct 10, 2023·0 cites·19 claims
- 4360US2025177445A1Engineered receptors specific to hla-e and methods of useA2 BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4459US2024180969A1Polypeptides targeting hla-a*11 and methods of use thereofA2 BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4559US2022370498A1Immune cells expressing receptor specific to class i mhc molecule and interfering rna for hla geneA2 BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4659US2024335471A1Vector systems for delivery of two polynucleotides and methods of making and using sameA2 BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4758US2025269027A1Compositions and methods for treating mesothelin positive cancersA2 BIOTHERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4857US2022315931A1Immune cells expressing receptor specific to class i mhc molecule and interfering rna for beta2 microglobulin geneA2 BIOTHERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4954US2024000938A1Adoptive cell therapy for treatment of cancer associated with loss of heterozygosityA2 BIOTHERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 5052US2024173352A1Cell-surface receptors responsive to loss of heterozygosityA2 BIOTHERAPEUTICS INC·Filed 2020·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →